Liver Cancer Cell Lines
Database

LCCL to predict drug response

Drug: Refametinib

DrugsAliasTargetsTargeted cellular functionClinical status in any tumor typeClinical status in HCCSupplierReference
Refametinib BAY 86-9766 MEK1/2 MAPK/ERK signaling Phase 1, 2 Phase 2 Selleck Chemicals S1089

Cell Line (34)
Cell LineAUCGI50
HepG20.5710.0
JHH10.670.45
HepaRG0.741.8
HCC.1.20.782.15
JHH50.781.8
Hep3B0.823.8
SNU3870.8310.0
SNU8860.8810.0
SNU1820.8910.0
Huh70.90.125
SNU3980.9110.0
JHH70.9210.0
Huh60.9210.0
SNU8780.932.9
JHH20.9410.0


LCCL transcriptomic subgroup:
CL1
CL2
CL3
undef.

Codebase Soc. Coop.
info@codebase.it